P683: A FIRST‐IN‐HUMAN PHASE 1 STUDY OF ORAL LOXO‐338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)

Jurczak, W. ; Alencar, A. J. ; Guru Murthy, G. S. ; Hoffmann, M. ; Pagel, J. M. ; Patel, V. ; Pauff, J. M. ; Zinzani, P. L. ; Le Gouill, S. ; Mato, A. R. ; Roeker, L. E.

HemaSphere, 2022-06, Vol.6, p.579-580 [Periódico revisado por pares]

Philadelphia, PA: Lippincott Williams & Wilkins

Texto completo disponível